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We have identiﬁed a novel germline mutation in the PTEN tumour suppressor gene. The mutation was identiﬁed in a patient
with a glioma, and turned out to be a heterozygous germline mutation of PTEN (Arg234Gln), without loss of heterozygosity
in tumour DNA. The biological consequences of this germline mutation were investigated by means of transfection studies of
the mutant PTEN molecule compared to wild-type PTEN. In contrast to the wild-type molecule, the mutant PTEN protein is
not capable of inducing apoptosis, induces increased cell proliferation and leads to high constitutive PKB/Akt activation, which
cannot be increased anymore by stimulation with insulin. The reported patient, in addition to glioma, had suffered from benign
meningioma in the past but did not show any clinical signs of Cowden disease or other hereditary diseases typically associated
with PTEN germline mutations. The functional consequences of the mutation in transfection studies are consistent with high
proliferative activity. Together, these ﬁndings suggest that the Arg234Gln missense mutation in PTEN has oncogenic properties
and predisposes to brain tumours of multiple lineages.
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PTEN, also designated as MMAC1 or TEP1, is a tumour suppres-
sor gene located on chromosome 10q23 (Li et al, 1997; Bonneau
and Longy, 2000). Somatic PTEN mutations have been identiﬁed
in a variety of human cancers including breast, prostate, thyroid
and endometrial carcinomas, malignant melanomas and gliomas
(Bonneau and Longy, 2000). Mutation of PTEN appears to occur
early in tumour development in endometrial cancer but late in
the development of gliomas. Germline mutations in PTEN have
also been found in the dominantly inherited Cowden, Lhermitte-
Duclos, and Bannayan-Zonana syndromes, which are characterised
by the formation of multiple benign tumours (Nelen et al, 1997).
Disruption of PTEN in the mouse results in early embryonic
lethality. PTEN heterozygous mice display hyperplastic features as
well as high tumour incidence suggesting that inactivation of PTEN
plays important roles in tumorigenicity (Di Cristofano et al, 1998;
Suzuki et al, 1998; Podsypanina et al, 1999). The PTEN gene
contains nine exons and encodes a 403-aa protein, which possesses
phosphatase activity on phosphotyrosyl and phosphoseryl/threonyl
residues (Li and Sun, 1997; Bonneau and Longy, 2000). PTEN is an
inefﬁcient protein phosphatase in vitro but is very active on highly
acidic substrates. The main PTEN substrate has proven to be phos-
phatidyl inositol (3,4,5)-triphosphate (PIP-3), which is the direct
product of PI-3-kinase (Maehama and Dixon, 1998).
It has been proven that cells lacking wild-type PTEN from glio-
mas are characterised by elevated levels of PIP-3 (Myers and
Tonks, 1997). As a consequence, the activity of protein kinase B
(PKB/Akt) was found to be elevated, resulting in prevention of
apoptosis (Stambolic et al, 1998). Introduction of wild-type PTEN
reduced the levels of PIP-3 and protein kinase B (Li and Sun,
1998). In addition, wild-type PTEN was found to suppress the
proliferation and the tumour growth of PTEN deﬁcient glioblasto-
ma cells, whereas mutant phosphatase inactive PTEN failed to
suppress cell growth (Cheney et al, 1998; Furnari et al, 1998). Thus,
two biological processes, namely cell proliferation and apoptosis
are partly regulated by PTEN activity.
In searching for PTEN mutations in human gliomas we detected a
heterozygous mutation (Arg234Gln) of PTEN in a patient with a
glioma. The mutation was present in tumour DNA, as well as in
DNA isolated from peripheral blood lymphocytes. No signs of
Cowden disease were found in the patient, nor did we ﬁnd any indi-
cations for loss of heterozygosity (LOH) of PTEN in tumour
material. The biological consequences of this germline mutation have
been evaluated by means of transfection studies of the mutant PTEN
molecule compared to wild-type PTEN. Our results suggest that this
mutation plays a role in regulating apoptosis and cell proliferation.
PATIENT AND METHODS
Patient and histology
In 1981 a 38-year old male, with an unremarkable medical history
and with no family history of brain tumours, presented with focal
seizures of the right arm and dysphasia. No neurological abnorm-
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www.bjcancer.comalities were found on examination. Anti-epileptic drug medication
resulted in a marked reduction of the seizures. In 1985 a CT brain
scan was made because of progressive headaches and memory difﬁ-
culties. A large right frontal lesion was found suggestive of a
meningioma; this was removed completely. The diagnosis of
meningioma was conﬁrmed by the pathologist, but there were no
signs of malignancy. In 1990 the seizures spread to the patient’s
right leg.
A CT scan revealed a non-enhancing lesion with slight mass
effect in the left frontal lobe; a low grade glioma was suspected.
The patient’s symptoms progressed and he underwent surgery for
this lesion in 1993. Histologic examination revealed tumour cells
with peri-nuclear unstained cytoplasm, with irregular round to oval
nuclei, with some mitotic activity (three per square mm). The
capillary network in the tumour was unremarkable and there was
no necrosis. This tumour was classiﬁed as an anaplastic oligoden-
droglioma. The patient underwent radiotherapy.
In 1998 the patient suffered a decline of cognitive functioning. A
new CT brain scan showed regrowth of the left frontal tumour,
which was again treated surgically. Histologic examination revealed
a similar proﬁle to that in 1993, but with more pleiomorphism of
the nuclei of the tumour cells, more mitotic activity (eight per
square mm), microvascular proliferation, and small areas of necro-
sis. The diagnosis was an anaplastic oligodendroglioma with signs
of ongoing de-differentiation.
He was treated with chemotherapy for residual tumour, but
after nearly a year there was further tumour growth. His clinical
condition is steadily deteriorating.
Tumour sample
Tumour samples were collected in the Department of Neurosur-
gery, University Medical Center, Utrecht, the Netherlands.
Immediately after removal, parts of the tumour were snap-frozen
in liquid nitrogen and stored at 7808C until required.
DNA extraction
Tumour tissue was cut into 10 mm thick sections and mounted
onto glass slides. Reference slides were stained with haematoxylin
and eosin and examined by the pathologist in order to grade the
tumour according to WHO criteria and for selecting tumour
regions for analysis. The marked slide was used to guide microdis-
sections. DNA extraction was carried out with the use of proteinase
K and phenol/chloroform. High molecular weight DNA of the
patient was also isolated from peripheral blood according to estab-
lished procedures.
LOH analysis
For LOH analysis, a total of six highly polymorphic markers from
the PTEN region were used: ﬁve microsatellite markers ﬂanking
PTEN (D10S1645, D10S579, D10S215, D10S603 and D10S541)
and the intragenic marker D10S2491. PCR reactions were
performed in a GeneAmp 9600 PCR System (PE Biosystems) in
a1 0 ml volume containing 30 ng genomic DNA as template,
25 ng of each oligonucleotide primer, 200 mM of each dNTP and
0.4 unit AmpliTaq Gold DNA polymerase (Perkin Elmer), in 16
AmpliTaq Gold buffer with 2.5 mM MgCl2. An initial denaturation
of 5 min at 958C was followed by 36 cycles of 30 s at 958C, 30 s at
558C, 30 s at 728C, and a ﬁnal extension step of 10 min at 728C.
Markers were analysed on an ABI Prism
TM 377 DNA Sequencer
(PE Biosystems) using GeneScan and Genotyper software.
Sequence analysis
Direct sequencing of the nine PTEN exons and their immediately
ﬂanking regions was performed using the oligonucleotide primers
published by Steck et al (1997). PCR reactions were performed
in a GeneAmp 9600 PCR System (PE Biosystems) in a 50 ml
volume containing 100 ng genomic DNA as template, 50 ng of
each oligonucleotide primer, 200 mM of each dNTP and 1.25 unit
AmpliTaq Gold DNA polymerase (Perkin Elmer), in 16AmpliTaq
Gold buffer with 2.5 mM MgCl2. An initial denaturation of 10 min
at 958C was followed by 35 cycles of 30 s at 958C, 30 s at 558C,
1 min at 728C, and a ﬁnal extension step of 10 min at 728C. For
the ampliﬁcation of exons 1 and 2, the annealing temperature
was 57 and 508C, respectively. Sequencing was performed on an
ABI Prism
TM 377 DNA Sequencer (PE Biosystems) using the
Rhodamine Terminator Cycle Sequencing Ready Reaction Kit,
according to the manufacturer’s instructions.
Constructs, transfections and proliferation assays
Wild-type and Arg234Gln mutant PTEN were cloned into the
pCDNA3 expression vector by using PCR primers containing
restriction sites. For wild-type PTEN the forward primer contained
a BamHI site, the reverse primer a XhoI site. The mutant site was
introduced by means of two partially overlapping primers contain-
ing the mutation and introducing an EcoRI site. The EcoRI site was
used to conﬁrm the presence of the mutation in the ﬁnal construct.
Sequences: PTEN FW: 5' CAAGGATCCACCATGACAGCCAT-
CATCAAAGAG 3'
PTEN RV: 5' CGTTGCCTCGAGTCAGACTTTTGTAATTTGTG-
TATG 3'
MUT PTEN FW: 5' GCCTGAATTCGAGGAATATATCTT-
CACCTTTAG 3'
MUT PTEN RV: 5' TTCCGAATTCAGGACCCACACGACAG-
GAAGACAAGTTCATGTACTTC 3'.
PCR was performed in a 50 ml volume containing 100 ng pSG5-
PTENwt as template, 50 ng of each oligonucleotide primer, 200 mM
of each dNTP and 1.25 unit AmpliTaq Gold DNA polymerase
(Perkin Elmer), in 16AmpliTaq Gold buffer with 2.5 mM MgCl2.
An initial denaturation of 10 min at 958C was followed by 25
cycles of 30 s at 958C, 30 s at 578C, 1.25 min at 728C, and a ﬁnal
extension step of 7 min at 728C. PCR products were separated on a
1% agarose gel, puriﬁed, and digested with XhoI and BamHI (wt),
or the two PCR products for mutant PTEN with BamHI and EcoRI
and with EcoRI and XhoI. Wt PTEN was cloned into BamHI/XhoI
digested pCDNA3 by direct ligation, and the mutant PTEN by
three-point ligation. Integrity of the wild-type and mutant forms
was conﬁrmed by sequencing the full inserts, as above. For trans-
fections, the plasmids were digested with XbaI, in order to
linearise them outside the neomycin resistance cassette and outside
the PTEN coding sequence.
U87 glioma cells, which lack functional PTEN were transfected
with the pcDNA expression constructs (which contains a neomycin
resistance gene) using Fugene-6 (Boehringer Mannheim), according
to the manufacturer’s instructions. Two days after transfection,
cells were put under selection using G418 (1.0 mg/ml). After
approximately 3 weeks of selection, stable selected cells were
checked for cell proliferation by seeding 5000 cells from the stable
transfectants and manual counting at days 4, 6, 8 and 11.
Western blotting
Equal numbers of U87 cells were lysed in boiling SDS sample
buffer, loaded on a 10% polyacrylamide gel, separated by electro-
phoresis and blotted onto nitrocellulose by standard methods.
PTEN protein was revealed using the anti-PTEN Antibody 9522
(Cell signalling Technology) and a Goat anti-rabbit-HPRO second
step antibody, followed by visualisation by enhanced chemilumi-
nescence (ECL, Amersham). For PKB assays, U87MG cells were
seeded and grown to subconﬂuency, serum-starved for 18 h, and
either left untreated or treated with insulin for 10 min then washed
with PBS twice and directly harvested in Leamlli sample buffer.
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tion of PKB by immunoblotting using an antibody against
phosphorylated serine 473. The phosphorylation of this residue
activates PKB/Akt.
Apoptosis assay
Expression plasmids that target PTEN to the cell membrane using
the CAAX motif were constructed in pcDNA by standard meth-
ods. Apoptosis assays were done as described (Kalejta et al,
1997). The CAAX constructs or empty vector (18 mg) were trans-
fected by electroporation (270 V; 960 uF) into BaF3 promyelocytic
cells, together with a Spectrin-GFP plasmid (2 mg). Two hours
after transfection viable cells were collected by Ficoll density
centrifugation, and cultured for another 24 h. The next day cells
were harvested and resuspended in 300 ml PBS to which 700 ml
ice cold 100% ethanol was added. Cells were incubated at
7208C for 2 h, washed and incubated with a propidium
iodide/RNAse solution for 30 min at 378C and put on ice in
the dark till analysis on a FACScan ﬂow cytometer. The number
of transfected apoptotic cells was enumerated by electronic gating
on GFP+ cells, and generating a cell cycle proﬁle for these cells.
The percentage of sub 2n cells was taken as a measure for the
percentage of apoptosis.
RESULTS
Mutation analysis and LOH
The PTEN gene from a patient with glioma was analysed. PCR of
all nine exons of the PTEN gene followed by sequencing revealed a
G to A (CGACGG?CGACAG) substitution at position 701 (PTEN
cDNA sequence U93051, GenBank) in exon 7, changing an argi-
nine (Arg) residue to a glutamine (Gln) at codon 234. Figure 1
depicts the sequence analysis showing the missense mutation
detected. The Arg234Gln (R234Q) mutation is located at the
surface of the protein of the so-called C-2 domain (Lee, 1999).
The mutation was found in DNA obtained from peripheral blood,
the meningioma and the two oligodendrogliomas of the patient.
The mutation has not been observed in 80 normal control chromo-
somes (data not shown), therefore it is unlikely to represent a
common polymorphism.
Taken together, this therefore indicates that the R234Q mutation
is a pathogenic germline mutation. No family studies could be
carried out. To determine whether the PTEN mutation detected
was associated with loss of heterozygosity in chromosome 10q,
microsatellite analysis was carried out using markers mentioned
in Materials and Methods. No LOH could be detected, which is
in agreement with the heterozygous nature of the mutation in
tumour material observed by DNA sequencing.
Cell proliferation analysis
In order to functionally characterise the consequence of the
R234Q mutation identiﬁed, we performed two different assays
concerning two processes, in which PTEN has been shown to play
a key role, namely cell proliferation and apoptosis. We cloned
wild-type and mutant PTEN into an expression plasmid and
stably transfected U87MG glioma cells that lack functional PTEN.
In this cell line, the PTEN gene carries a mutation in the splice
donor site of intron 3, resulting in deletion of exon 3 in the
mature transcript, leading to an unstable, nonfunctional protein
that can only be detected at low levels. Western blot analysis
revealed that PTEN levels in the transfectants were roughly equal
to each other (Figure 2) and similar to cell lines that contain
functional PTEN (not shown). In contrast, the U87 mother cell
line contains lower levels of (non-functional) PTEN compared
to the transfectants (Figure 2).
The wild-type and mutant PTEN transfectants were compared
for their growth properties. By counting the number of cells over
a 2-week period, it became apparent that the mutant cells prolifer-
ated at a roughly ﬁve-fold higher rate than cells transfected with
wild-type PTEN (Figure 3). Thus, the R234Q mutation in PTEN
that we found permits cells to proliferate at a much higher rate.
Apoptosis
The wild-type and mutant PTEN were cloned into a so-called
CAAX vector to target them to the cell membrane. Using BaF3
promyelocytic cells, which are IL-3 dependent and sensitive to
apoptosis, we investigated the consequence of these forms of PTEN
for apoptosis. In order to identify transfected cells, the PTEN mole-
cules were co-transfected with a spectrin-GFP construct. Gating on
GFP positive cells thus permitted investigating only transfected
cells. As shown in Figure 4, cells transfected with an empty vector
(together with Spectrin-GFP), have approximately 18% apoptotic
cells. Transfection of wild-type PTEN almost doubles the percen-
tage of apoptotic cells (32%), in contrast mutant PTEN does not
induce any apoptosis (16% of sub 2n cells) and in some experi-
ments the percentage of apoptotis after transfection of the
mutant was even lower than in cells transfected with Spectrin-
GFP alone.
PKB/Akt activity
U87MG cells stably expressing either wild-type PTEN or the
R234Q mutant were compared with respect to the phosphorylation
status of PKB. Phosphorylation of PKB at threonine 308 and serine
473 is indicative for the activity of PKB (reviewed in Chan et al,
1999). As reported previously ((Maier et al, 1999) and data not
shown) parental U87MG cells displayed elevated levels of PKB
phosphorylation which could still be further elevated by treatment
of cells with insulin for 10 min (see Figure 5). Stable expression of
wild-type PTEN did not signiﬁcantly alter PKB regulation. In
contrast however, expression of the R234Q mutant resulted in a
further increase in PKB phosphorylation that could not be induced
further by insulin treatment.
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Figure 1 Identiﬁcation of an Arg234Gln germline PTEN mutation in a
patient with multiple brain tumours. A partial sequence of exon 7, obtained
from tumour (glioma) DNA is shown. In the sequence (which is in reverse
orientation), the single base change (C to T) is indicated by an arrow. The
heterozygous peak corresponds to a G to A substitution at position 701 in
the PTEN coding sequence, and results in an arginine to glutamine amino
acid change at codon 234. Note the heterozygous state of the missense
mutation, suggesting that there is no LOH of PTEN in the tumour.
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Here we report on a novel PTEN mutation that was found as a
germline mutation in a patient with meningioma and glioma. To
our knowledge this is the ﬁrst germline mutation reported for
brain tumours of multiple lineages. The mutation changes an argi-
nine residue to a glutamine in the C-2 domain of PTEN. This
changes the charge of that region (from positive to neutral). Func-
tions of the C-2 region may involve membrane targeting through
interactions with membrane phospholipids or association with as
yet unknown proteins (Lee, 1999). It has also been shown that
the C-2 domain functions to position the phosphatase domain
correctly with respect to its substrates. Therefore, mutations in
the C-2 domain could alter the overall enzymatic activity of PTEN,
without necessarily affecting its phosphatase activity.
We demonstrate that this mutation has functional consequences
because the mutant molecules allow cells to proliferate at much
higher levels and do not induce or prevent apoptosis. Given that
mice with a targeted PTEN mutation on one allele and a wild-type
PTEN molecule on the other allele show abnormalities (Di Cristo-
fano et al, 1998, 1999), the heterozygous nature of the mutation in
the patient does not diminish the importance of the functional
ﬁndings. The functional consequences of the mutation we have
found may help explain why the tumour arose. Of course, it is
possible that this mutation has nothing to do with the develop-
ment of the tumour, or that this is a syndrome with a very low
penetrance. However, it seems likely that this mutation also has
functional consequences in the tumour. Competition for limited
substrates or associated molecules may interrupt normal PTEN
function sufﬁciently to lead to increased proliferation and dimin-
ished apoptosis. In fact, the mutant molecule is incapable of
inducing apoptosis in BaF/3 cells, which contain endogenous func-
tional PTEN. In some experiments the percentage of apoptotic cells
after transfection of R234Q PTEN was even lower than GFP alone,
perhaps because endogenous PTEN activity was somewhat inhib-
ited. Another indication that this mutation may not be solely a
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Figure 2 Western blot of stably transfected U87-MG glioma cells. The
U87 glioma cell has a dysfunctional PTEN molecule and was transfected
with R234Q mutant (lane 2) or wild-type (lane 1). Stable transfectants ex-
press higher levels of PTEN than the parental line (lane 3). The 54 kD
PTEN band is indicated by an arrow.
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Figure 3 R234Q Mutant PTEN allows higher levels of proliferation than
wild-type PTEN. The stable U87 transfectants were grown under neo-se-
lection and 5000 cells were seeded on day 0. Pints cells were harvested
and counted at the indicated time.
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Figure 4 Mutant PTEN does not induce apoptosis, whereas wild-type
does. BAF/3 cells were transfected with Spectrin-GFP, together with empty
vector control (A) CAAX-PTEN wild-type (B), CAAX-PTEN mutant (C).
Cell cycle proﬁles for propidium iodide stained cells, electronically gated on
GFP+ cells are shown.
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Figure 5 Increased constitutive PKB activity, but lack of insulin-induced
PKB activity in R234Q PTEN transfectants. U87MG transfected wild-type
cells (lanes 1 and 2), U87MG cells transfected with normal PTEN (lanes
3 and 4) and mutant PTEN (lanes 5 and 6) were seeded and grown to sub-
conﬂuency, serum-starved for 18 h and either left untreated (lanes 1, 3, 5)
or treated with insulin (lanes 2, 4, 6) for 10 min then washed with PBS
twice and directly harvested in Leamlli sample buffer. Fifty mg of protein
were analysed by SDS–PAGE for phosphorylation of PKB by immunoblot-
ting using an antibody against phosphorylated serine 473. The phosphoryla-
tion of this residue activates PKB/Akt. The transfection of wild-type PTEN
has little effect, whereas the R234Q mutant induces constitutive phosphor-
ylation of PKB, which cannot be increased further by insulin treatment.
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from experiments investigating PKB activity. In R234Q PTEN
transfectants, PKB activity could not be induced by insulin treat-
ment, in contrast to parental cells or cells transfected with wt
PTEN. This result suggests that the R234Q mutation acts to inhibit
the residual PTEN activity present in U87MG cells and can there-
fore be considered as acting as a negative competitor. Thus, the
functional consequences of the mutation in transfection studies
are consistent with high proliferative activity. Together, these ﬁnd-
ings suggest that the Arg234Gln missense mutation in PTEN has
oncogenic properties.
The main PTEN substrate has proved to be phosphatidyl inosi-
tol (3,4,5)-triphosphate (PIP-3) (Myers and Tonks, 1997).
Previously, it has been shown that glioma cells lacking wild-type
PTEN are characterised by elevated levels of PIP-3 (Li and Sun,
1998). As a consequence, the activity of protein kinase B (PKB/
Akt) was found to be elevated, resulting in prevention of apoptosis
and increased proliferation. Our results ﬁt this picture in that
U87MG cells stably transfected with the R234Q mutant PTEN also
show increased proliferation and increased constitutive PKB activ-
ity.
One of the main functions of PTEN is to keep PIP-3 levels low.
Loss of PTEN function results in increased PIP-3 levels, leading to
hyperactive PKB/Akt. The mutation we have found may similarly
affect PTEN activity, ﬁnally resulting in increased PKB activity,
increased cell proliferation, and diminished apoptosis.
Not many PTEN mutations described in the literature have
been associated with the C-2 domain, although Lee et al
(1999) reported that mutagenesis of the C-2 domain reduced
the tumour suppressive activity of PTEN. Our ﬁndings are
consistent with these results. It is tempting to speculate, based
on the X-ray crystallography model of PTEN (see Figure 6), that
the C-2 loop can associate with other proteins. Interestingly the
mutation is exactly in the middle of the loop, at a site readily
accessible for interaction with other molecules. Future research
will undoubtedly identify such C-2 domain-interacting molecules,
most likely further explaining the oncogenic nature of the PTEN
mutation we have described here. It has been proposed that
mutation of basic residues in the C-2 domain reduces the
membrane afﬁnity of PTEN and its ability to suppress the
growth of glioma tumour cells (Lee et al, 1999).
Germline mutations of the PTEN gene are responsible for
several inherited conditions, including Cowden disease, Banna-
yan-Zonana syndrome and Lhermitte-Duclos disease. Here we
present a patient with a heterozygous PTEN germline mutation
but with no signs of any of these disorders. The patient had an
oligodendroglioma, and, in the past, a benign meningioma. The
PTEN gene is a tumour suppressor gene and inactivation of both
alleles is required for neoplastic transformation. An inherited
mutation in one allele with somatic loss of the second allele may
result in oncogenesis. Loss of the second allele in human gliomas
often occurs by deletion of a part of chromosome 10. However,
no LOH could be detected in tumour-derived DNA samples. Inac-
tivation of PTEN by a somatic point mutation could also be
excluded, since sequencing of all PTEN coding exons in tumour
DNA revealed no changes other than the Arg234Gln germline
mutation. One may hypothesise that promoter hypermethylation
might function as the second hit at the PTEN gene in the genesis
of the patient’s tumour. Alternatively, a somatic point mutation
could be present in the regulatory sequences of the gene. On the
other hand, it has been reported that in a mouse model, inactiva-
tion of one PTEN allele has important consequences for cell
survival and proliferation (Di Cristofano et al, 1999). This suggests
that PTEN haplo-insufﬁciency could be an important factor in cell
transformation.
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